United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).
about
Quality of life in patients with chronic thromboembolic pulmonary hypertensionAdaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands.The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.Exercise training in patients with pulmonary arterial hypertension: a case reportSubcutaneous treprostinil is well tolerated with infrequent site changes and analgesicsSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertensionQuality of life as a prognostic marker in pulmonary arterial hypertensionPhysician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional surveyComparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertensionInterleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension.A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension.Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension.Applying Rasch analysis to evaluate measurement equivalence of different administration formats of the Activity Limitation scale of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).Updating clinical endpoint definitions.Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnairePhysical Activity and Symptoms in Pulmonary Arterial Hypertension.Health-related quality of life and patient-reported outcomes in pulmonary arterial hypertension.An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertensionemPHasis-10: development of a health-related quality of life measure in pulmonary hypertension.Sleep quality, depression, and quality of life in patients with pulmonary hypertension.Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population.Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study.Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden.Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.Phase I safety study of ranolazine in pulmonary arterial hypertension.Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.Health-related quality of life of patients with pulmonary arterial hypertension associated with CHD: the multicentre cross-sectional ACHILLE study.Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension.Anxiety, Depression, and Health-Related QOL in Patients Diagnosed with PAH or CTEPH.Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.Health-Related Quality of Life in Pulmonary Hypertension and Its Clinical Correlates: A Cross-Sectional Study.
P2860
Q26748611-376A6C8B-D6C0-4BB1-9DF5-B5246D4E5105Q27342609-747EFD8F-5280-4DA5-AF20-FCA2C145AF4BQ27497418-B6539B71-95AD-4750-9BFC-228AF5F5E9E8Q30251818-9FB2E8EB-7F84-4006-9882-7F0B61E3E3FDQ33752301-53001ADF-DFA6-4683-BFFC-EA3618E1577DQ33806168-44B73396-36C6-49EE-9CCF-C1EDC4F09891Q33965859-D338A775-85B3-4157-B76D-16EDD8FAA403Q34207690-C31886BF-0F7B-42F8-BBF0-FD8F13690A6EQ34782507-375DEA7B-5A8D-47FB-9214-318F2058BFA3Q35172737-3CFC727A-2EBF-4DA1-8986-869B598DD10CQ35565086-592026F9-A2A7-488B-93BD-E63A2007285AQ35792816-FBACDF3B-9595-4CC3-B8A8-4753D0D82FA6Q36411205-C20B4010-3BF0-43AA-954F-6F05F0CF0BDEQ36421934-6A324F60-A9E1-42EB-9E25-E4B36E5BF791Q36447357-D7ECDF9A-1BE1-49D5-809A-C0AE7DB1F4DAQ36594582-916A7152-F0AF-44FC-9789-BA954186EF4AQ36783489-77F81936-0598-48E0-A7DF-070130474B69Q36810813-96244295-0ACF-4C68-8D3C-025F06107A4AQ37129644-F9D645BD-3E0A-4F2C-909B-E9F5C853569FQ37166393-ABBD42BA-9BEE-4FAB-B591-8F36CFD4B2F6Q37215969-DAD0EDC7-7F67-4EA3-B1B5-C00E9A4A42ABQ37555352-66730BFA-0460-4F83-B193-D316C79ABD14Q37676356-E654817B-659D-44B0-AFB4-B7DFDB68790CQ37822694-28FF1795-AE71-4FF9-94A2-D2F6DE9F1BB1Q37910292-6D9B12FB-CED1-443E-9081-937195038D16Q37987390-0D634817-954C-4E39-AD20-03D2136A7897Q38057110-AF2023CE-D505-48AF-BA96-2904DDA867DBQ38180650-A58DBF4B-0EA1-44BC-9D61-441414AFEA5EQ38398135-F27520B0-88FE-4E6E-B97B-B978A9FFD26DQ38621458-3E5AB4A2-BE47-4D65-AC32-879E2223779EQ38775948-F02E7F88-09BC-486E-8AD0-8F0C42B5DF9CQ39061553-4C40CAA7-DF0D-41BC-AB7A-71B6C20DE88FQ47601963-05582C02-9C8A-42A7-944E-D2D952E8C60BQ48418851-AF9DF3B0-1DFE-4EF4-A3AC-C536865D7761Q55000190-C3145E3A-988A-4AB5-AFD2-F38C9F81A3DC
P2860
United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
United States validation of th ...... sion Outcome Review (CAMPHOR).
@en
United States validation of the Cambridge Pulmonary Hypertension Outcome Review
@nl
type
label
United States validation of th ...... sion Outcome Review (CAMPHOR).
@en
United States validation of the Cambridge Pulmonary Hypertension Outcome Review
@nl
prefLabel
United States validation of th ...... sion Outcome Review (CAMPHOR).
@en
United States validation of the Cambridge Pulmonary Hypertension Outcome Review
@nl
P2093
P1476
United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
@en
P2093
David M Meads
Kamran Rizvi
Mardi Gomberg-Maitland
Sonal Chandra
Stephen P McKenna
P304
P356
10.1016/J.HEALUN.2007.10.004
P577
2008-01-01T00:00:00Z